Skip to content

Mitochondrial DNA as a Biomarker of Sepsis Severity

Mitochondrial DNA as a Biomarker of Sepsis Severity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03077672
Acronym
MBOSS
Enrollment
1304
Registered
2017-03-13
Start date
2017-02-10
Completion date
2020-12-22
Last updated
2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection, Sepsis, Sepsis Syndrome, Septic Shock, Severe Sepsis

Keywords

Mitochondrial DNA, Lactate, Mortality, Emergency Department, Intensive Care Unit, Triage, Organ Dysfunction, Biomarker, Prognosis

Brief summary

Mitochondria are organelles (a specialized subunit of a cell) responsible for providing cells with energy. For reasons not yet understood, mitochondria will release their DNA into blood in response to cellular injury or cell death. With a simple blood draw, investigators can measure the amount of mitochondrial DNA in a patient's blood. The investigators' hypothesis, is that mitochondrial DNA can be used as a surrogate marker of cellular injury to predict patient outcomes. The investigators intend to test their hypothesis by measuring mitochondrial DNA in adult patients presenting to the Emergency Department with sepsis (a life-threatening condition due to an infection) and observing their hospital course.

Detailed description

Despite the advances of modern medicine, sepsis persists as one of the leading causes of death in the United States and poses a significant burden on U.S. health care, accounting for more than $24 billion of total hospital costs in 2013. The high mortality and cost of treating sepsis at least partially stems from the consequences of delayed diagnosis. Unfortunately, this delay is attributable to the broad clinical manifestations of the syndrome and the absence of a specific test for sepsis. Realizing this, The Society of Critical Care Medicine and the European Society of Intensive Care Medicine have released guidelines emphasizing the need for diagnostic approaches aimed at the early detection of sepsis. The hope is that early recognition will allow for more aggressive upfront management thereby improving patient outcomes. In 2013, Nakahira et al showed that circulating cell-free mitochondrial DNA levels are associated with sepsis and mortality in patients admitted to the ICU. In contrast to that study, the purpose here is to determine whether circulating cell-free mitochondrial DNA and other biomarkers are associated with the severity of sepsis and 28-day mortality in patients presenting to the ED with sepsis. To accomplish this task, the investigators intend to prospectively collect specimens from patients presenting to NYP-Weill Cornell and NYP-Brooklyn Methodist with suspected sepsis.

Interventions

None listed

Sponsors

New York Presbyterian Hospital
CollaboratorOTHER
New York Presbyterian Brooklyn Methodist Hospital
CollaboratorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Weill Medical College of Cornell University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults presenting to the Emergency Department with suspected sepsis.

Exclusion criteria

* Pregnancy. * Patients with limitations of care at the time of specimen collection.

Design outcomes

Primary

MeasureTime frameDescription
Hospital Mortality60 DaysAll-Cause

Secondary

MeasureTime frameDescription
Association with severity of illness severity of illness as determined by MEDS Score3 DaysMEDS Score
Association with severity of illness as determined by SOFA Score3 DaysSOFA Score
Association with severity of illness as determined by qSOFA Score3 DaysqSOFA
ICU-Free Days28 DaysNumber of days free from ICU Admission
Triage Decision3 DaysIf the patient was discharged home or admitted to the floor, a step-down unit, or an ICU
Need for Supportive MeasuresUp to 60 DaysNIPPV, Mechanical Ventilation, Vasopressors, CVVHD, iNO, ECMO

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026